Navigation Links
FDA Panel to Vote on Drugs Said to Prevent Prostate Cancer
Date:12/1/2010

WEDNESDAY, Dec. 1 (HealthDay News) -- A U.S. Food and Drug Administration advisory panel is expected to decide Wednesday whether to approve two drugs for the prevention of prostate cancer, the third highest cancer killer of men.

Avodart and Proscar, manufactured by GlaxoSmithKline and Merck, respectively, are already approved to treat enlarged prostates. The drug makers say their research shows the drugs also lower the risk of prostate cancer by more than 20 percent.

FDA regulators have several concerns, the Associated Press reported. For one thing, black men, who are at high risk for the disease, were underrepresented in the clinical trials. "The applicability to African-American men is not known due to marked under-representation," the FDA's online review stated.

Blacks made up just 4 percent of Merck's patients and only 2 percent of Glaxo's patients, according to the AP.

The panel of outside experts assembled by the FDA is also likely to discuss the overall value of preventing low-grade tumors. According to the FDA, more than three-quarters of the tumors the drugs prevent are slow-growing, meaning they are non-aggressive and probably not life-threatening for anyone with a life expectancy of less than 20 years.

But even if the tumors aren't aggressive, Glaxo has said they often involve unnecessary treatment and biopsies, or surgical procedures, to diagnose cancer, that pose risks of their own.

Also, slightly more aggressive tumors were seen in men taking Avodart and Proscar, compared with those taking placebo pills, according to the FDA. But the pharamaceutical companies say the drugs simply make those tumors easier to detect because they shrink the prostate.

The U.S. National Cancer Institute estimates that 217,730 men will be diagnosed with prostate cancer this year and 32,050 men will die of it.

The FDA usually follows the recommendations of its expert panels, although it is not required to do so. If given the go-ahead, Avodart and Proscar would be the first drugs to win FDA approval for prevention of prostate cancer.

More information

For more on prostate cancer, visit the U.S. National Library of Medicine.

-- Margaret Steele

SOURCES: U.S. Food and Drug Administration; Associated Press


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. FDA Panel to Vote on Drugs to Prevent Prostate Cancer
2. Medicare Panel Endorses Vaccine for Prostate Cancer Patients
3. Teens Should Get Meningitis Booster Shot: CDC Panel
4. Expert Panel Links Popular Bone Drugs to Rare Fracture
5. FDA Panel to Mull Ban on Diet Drug Meridia
6. Experts Support FDA Panels Backing of New Blood Thinner
7. Avandia Raises Heart Risk But Should Stay on Market, FDA Panel Finds
8. FDA Panel Seems Skeptical Over Key Avandia Data
9. FDA Panel Appears Skeptical Over Key Avandia Data
10. NJIT professor heads panel studying sudden car acceleration
11. FDA Panel Votes Against Approval of Female Viagra
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... (PRWEB) , ... March 30, 2017 , ... Although many ... concerns, equally as many are wary of baring their skin for other reasons, including ... at West Dermatology can help get the skin prepared for the summer weather and ...
(Date:3/30/2017)... Philadelphia, PA (PRWEB) , ... March 30, 2017 ... ... Wharton School is expanding its educational offerings of corporate finance programs to address ... a new program, will help executives increase their knowledge of sophisticated corporate finance ...
(Date:3/30/2017)... , ... March 30, 2017 , ... ... the Academy of Nutrition and Dietetics (AND), will join nonprofit Seafood Nutrition Partnership ... America,” a live webinar designed to help nutrition educators and students inform consumers ...
(Date:3/29/2017)... ... 29, 2017 , ... During the last week of March, Chad Kawa, MD ... individuals in the local community. , Colon cancer is the second leading cause ... cancer while it is small, confined and easier to treat. If you are 50 ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Professional Squash Association, the ... New York City-based sports and entertainment marketing firm Leverage Agency as its exclusive ... the Professional Squash Association (PSA), which includes first-time ever title sponsorship, naming rights, ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... HOUSTON , March 29, 2017  The leader ... announced that Drs. Sam Daher , Manal ... and David Couchat will be the featured microlecture ... the upcoming American Association of Orthodontists (AAO) Annual Session, ... to attend the microlectures beginning daily at 11:20 a.m. ...
(Date:3/29/2017)... ALBANY, New York , March 29, 2017 ... has recently published a report, which provides an ... According to the study, nearly 242 companies are ... highly fragmented and competitive. With the leading companies, ... and Purdue Pharma LP, focusing aggressively on various ...
(Date:3/29/2017)... 29, 2017 Varian Medical Systems (NYSE: ... the second quarter of fiscal year 2017 following the close ... release will be followed by a teleconference available to all ... a link to the conference call webcast will be available ... the teleconference call and replay: ...
Breaking Medicine Technology: